12 West Capital Management LP lowered its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 2.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 246,875 shares of the biotechnology company's stock after selling 5,974 shares during the period. Repligen comprises 3.7% of 12 West Capital Management LP's portfolio, making the stock its 10th largest position. 12 West Capital Management LP owned 0.44% of Repligen worth $35,535,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of RGEN. Signaturefd LLC grew its position in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in Repligen during the 4th quarter valued at $29,000. UMB Bank n.a. grew its holdings in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Global Retirement Partners LLC increased its position in shares of Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 129 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Repligen in the 4th quarter valued at about $55,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Price Performance
RGEN traded down $2.10 on Friday, reaching $130.00. The company had a trading volume of 753,355 shares, compared to its average volume of 707,222. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The company has a market capitalization of $7.30 billion, a P/E ratio of -254.90, a PEG ratio of 4.54 and a beta of 1.27. The company has a fifty day moving average of $140.76 and a 200-day moving average of $145.82. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently commented on RGEN shares. Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Finally, Royal Bank of Canada boosted their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $176.82.
Check Out Our Latest Report on Repligen
Insider Buying and Selling
In other Repligen news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is owned by corporate insiders.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
